NCT01078974View on ClinicalTrials.gov

Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

September 30, 2015

Study Completion Date

March 31, 2016

Conditions
Waldenstrom's Macroglobulinemia
Interventions
DRUG

pomalidomide

Taken orally once a day

DRUG

dexamethasone

Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15

DRUG

rituximab

Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Steven P. Treon, MD, PhD

OTHER